Captrust Financial Advisors Raises Stock Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Captrust Financial Advisors boosted its position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 84.6% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 17,394 shares of the specialty pharmaceutical company’s stock after purchasing an additional 7,969 shares during the period. Captrust Financial Advisors’ holdings in Supernus Pharmaceuticals were worth $629,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Smartleaf Asset Management LLC raised its stake in Supernus Pharmaceuticals by 219.1% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,267 shares of the specialty pharmaceutical company’s stock worth $47,000 after purchasing an additional 870 shares during the period. Mark Sheptoff Financial Planning LLC acquired a new stake in shares of Supernus Pharmaceuticals during the fourth quarter valued at about $52,000. Headlands Technologies LLC increased its position in shares of Supernus Pharmaceuticals by 203.0% during the fourth quarter. Headlands Technologies LLC now owns 1,515 shares of the specialty pharmaceutical company’s stock valued at $55,000 after acquiring an additional 1,015 shares during the last quarter. Newbridge Financial Services Group Inc. acquired a new stake in shares of Supernus Pharmaceuticals during the fourth quarter valued at about $72,000. Finally, Venturi Wealth Management LLC acquired a new stake in shares of Supernus Pharmaceuticals during the fourth quarter valued at about $92,000.

Insider Activity at Supernus Pharmaceuticals

In related news, SVP Jonathan Rubin sold 927 shares of Supernus Pharmaceuticals stock in a transaction that occurred on Friday, February 21st. The shares were sold at an average price of $39.15, for a total value of $36,292.05. Following the completion of the transaction, the senior vice president now owns 7,853 shares in the company, valued at $307,444.95. The trade was a 10.56% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 8.80% of the company’s stock.

Supernus Pharmaceuticals Stock Performance

Shares of SUPN stock opened at $33.43 on Friday. The stock has a market capitalization of $1.87 billion, a P/E ratio of 31.24 and a beta of 0.74. The company has a 50 day moving average price of $31.88 and a 200 day moving average price of $34.83. Supernus Pharmaceuticals, Inc. has a fifty-two week low of $25.53 and a fifty-two week high of $40.28.

Wall Street Analyst Weigh In

SUPN has been the subject of a number of recent analyst reports. StockNews.com upgraded shares of Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Friday. Cantor Fitzgerald reiterated a “neutral” rating and set a $36.00 price target on shares of Supernus Pharmaceuticals in a research report on Wednesday, February 26th.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.